CL2019003743A1 - Formas de dosificación oral y de liberación controlada gastrorresistentes. - Google Patents

Formas de dosificación oral y de liberación controlada gastrorresistentes.

Info

Publication number
CL2019003743A1
CL2019003743A1 CL2019003743A CL2019003743A CL2019003743A1 CL 2019003743 A1 CL2019003743 A1 CL 2019003743A1 CL 2019003743 A CL2019003743 A CL 2019003743A CL 2019003743 A CL2019003743 A CL 2019003743A CL 2019003743 A1 CL2019003743 A1 CL 2019003743A1
Authority
CL
Chile
Prior art keywords
dosage forms
controlled release
gastro
subject
oral dosage
Prior art date
Application number
CL2019003743A
Other languages
English (en)
Inventor
Nadine Noel
Sandra Werner
Emmanuelle Georgi
Jay Saoud
Remy Luthringer
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of CL2019003743A1 publication Critical patent/CL2019003743A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Abstract

LA PRESENTE DESCRIPCIÓN SE REFIERE A FORMAS DE DOSIFICACIÓN DE LIBERACIÓN CONTROLADA GASTRORRESISTENTES QUE COMPRENDEN EL COMPUESTO (I); O UNA SAL Y/O UN SOLVATO FARMACÉUTICAMENTE ACEPTABLE DE ESTE, LAS PROPIEDADES FARMACOCINÉTICAS DE ESTAS FORMAS DE DOSIFICACIÓN, Y SU PREPARACIÓN. LAS NUEVAS FORMAS DE DOSIFICACIÓN DESCRITAS EN LA PRESENTE SON ÚTILES PARA REDUCIR EL RIESGO DE PROLONGACIÓN QT EN UN SUJETO Y PARA TRATAR UN TRASTORNO EN UN SUJETO QUE LO NECESITA, P. EJ., UN SUJETO DIAGNOSTICADO CON ESQUIZOFRENIA, POR EJEMPLO, EN EL TRATAMIENTO DE LOS SÍNTOMAS NEGATIVOS EN UN SUJETO DIAGNOSTICADO CON ESQUIZOFRENIA QUE TIENE EL GENOTIPO CYP2D6 EM.
CL2019003743A 2017-06-21 2019-12-18 Formas de dosificación oral y de liberación controlada gastrorresistentes. CL2019003743A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762523204P 2017-06-21 2017-06-21

Publications (1)

Publication Number Publication Date
CL2019003743A1 true CL2019003743A1 (es) 2020-07-03

Family

ID=62904624

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003743A CL2019003743A1 (es) 2017-06-21 2019-12-18 Formas de dosificación oral y de liberación controlada gastrorresistentes.

Country Status (13)

Country Link
US (2) US11464744B2 (es)
EP (1) EP3641732A1 (es)
JP (2) JP2020525436A (es)
CN (1) CN111511353A (es)
AU (1) AU2018290287A1 (es)
BR (1) BR112019027398A2 (es)
CA (1) CA3067031A1 (es)
CL (1) CL2019003743A1 (es)
CO (1) CO2019014496A2 (es)
IL (2) IL271606B1 (es)
PE (1) PE20200732A1 (es)
UA (1) UA127349C2 (es)
WO (1) WO2018237207A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201704332YA (en) 2014-12-02 2017-06-29 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
WO2023154927A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
KR927002347A (ko) 1989-10-27 1992-09-03 레이몬드 지. 아너 (n-프탈이미도알킬) 피페리딘
RU2257384C2 (ru) 2000-02-29 2005-07-27 Мицубиси Фарма Корпорейшн Новые производные циклического амида
AR057350A1 (es) 2005-06-06 2007-11-28 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
BRPI1012196B1 (pt) * 2009-05-18 2021-11-30 Sublimity Therapeutics Limited Composição compreendendo gotas de óleo
AR081935A1 (es) 2010-06-16 2012-10-31 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada
HUE058736T2 (hu) 2010-07-20 2022-09-28 Minerva Neurosciences Inc Gyûrûs amidszármazékok alkalmazási módszerei szigma receptor közvetített rendellenességek kezelésére
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
US20120040008A1 (en) * 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
WO2012123922A1 (en) 2011-03-17 2012-09-20 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
CN104586771B (zh) * 2013-10-30 2018-01-16 广州朗圣药业有限公司 一种盐酸坦洛新缓释微丸制剂
MA39987A (fr) * 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
JP6531093B2 (ja) 2014-05-16 2019-06-12 武田薬品工業株式会社 含窒素複素環化合物
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
KR102425303B1 (ko) * 2014-08-13 2022-07-25 세다르스-신나이 메디칼 센터 항-메탄생성 조성물 및 그것의 용도
SG11201704332YA (en) 2014-12-02 2017-06-29 Minerva Neurosciences Inc Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
SG10202011470UA (en) 2016-05-25 2021-01-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
EP3840835A1 (en) 2018-08-21 2021-06-30 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection

Also Published As

Publication number Publication date
WO2018237207A1 (en) 2018-12-27
US20190038561A1 (en) 2019-02-07
RU2020102015A (ru) 2021-07-21
CN111511353A (zh) 2020-08-07
RU2020102015A3 (es) 2021-10-04
IL271606B1 (en) 2024-01-01
IL308650A (en) 2024-01-01
UA127349C2 (uk) 2023-07-26
JP2023175778A (ja) 2023-12-12
US20220401368A1 (en) 2022-12-22
IL271606A (en) 2020-02-27
CA3067031A1 (en) 2018-12-27
AU2018290287A1 (en) 2020-01-16
EP3641732A1 (en) 2020-04-29
BR112019027398A2 (pt) 2020-07-07
JP2020525436A (ja) 2020-08-27
PE20200732A1 (es) 2020-07-23
US11464744B2 (en) 2022-10-11
CO2019014496A2 (es) 2020-04-01

Similar Documents

Publication Publication Date Title
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
CL2019003743A1 (es) Formas de dosificación oral y de liberación controlada gastrorresistentes.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
GT201500086A (es) Análogos de 2'-cloro nucleósido para infección por vhc
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
AR100006A1 (es) Derivados de tubulisina
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2015001923A1 (es) Uso de crenolanib para el tratamiento de trastornos proliferativos que tiene flt3 mutado
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
AR101740A1 (es) Terapia de combinación y composiciones
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
NI201800071A (es) Compuestos de isoindol
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
UY35354A (es) Combinaciones que comprenden compuestos maba y corticosteroides
ECSP17044282A (es) Formulación de relación fija de insulina glargina/lixisenatida
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
UY35677A (es) Combinaciones que comprenden compuestos maba y corticosteroides
DOP2017000219A (es) Formulacion de combinacion de tesofensina y betabloqueante
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
DOP2014000030A (es) Procedimientos para la fabricación de medicamentos útiles para el tratamiento de infecciones virales